Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
Journal
BMC cancer
Journal Volume
16
Journal Issue
1
Date Issued
2016-11-07
Author(s)
Abstract
Vorinostat, a histone deacetylase (HDAC) inhibitor, is a promising agent for cancer therapy. Combining vorinostat with cisplatin may relax the chromatin structure and facilitate the accessibility of cisplatin, thus enhancing its cytotoxicity. Studies have not yet investigated the effects of the combination of vorinostat and cisplatin on small cell lung cancer (SCLC).
Subjects
Cisplatin; Combination therapy; HDAC inhibitor; SCLC; Vorinostat
SDGs
Publisher
BMC
Type
journal article